Log in

NASDAQ:SNGXSoligenix Stock Price, Forecast & News

$2.31
+0.05 (+2.21 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.15
Now: $2.31
$2.36
50-Day Range
$1.76
MA: $2.12
$2.61
52-Week Range
$0.85
Now: $2.31
$3.54
Volume574,213 shs
Average Volume2.42 million shs
Market Capitalization$66.90 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.
Read More
Soligenix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNGX
CUSIPN/A
Phone609-538-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.60 million
Book Value$0.07 per share

Profitability

Net Income$-9,360,000.00
Net Margins-351.69%

Miscellaneous

Employees14
Market Cap$66.90 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable
$2.31
+0.05 (+2.21 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Soligenix (NASDAQ:SNGX) Frequently Asked Questions

How has Soligenix's stock been impacted by COVID-19 (Coronavirus)?

Soligenix's stock was trading at $2.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SNGX stock has decreased by 9.1% and is now trading at $2.31.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Soligenix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Soligenix
.

When is Soligenix's next earnings date?

Soligenix is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Soligenix
.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) announced its quarterly earnings results on Friday, May, 15th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.21. The biopharmaceutical company had revenue of $0.90 million for the quarter. Soligenix had a negative return on equity of 542.83% and a negative net margin of 351.69%.
View Soligenix's earnings history
.

What price target have analysts set for SNGX?

2 brokerages have issued twelve-month price targets for Soligenix's shares. Their forecasts range from $2.00 to $4.00. On average, they anticipate Soligenix's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 29.9% from the stock's current price.
View analysts' price targets for Soligenix
.

Has Soligenix been receiving favorable news coverage?

Media headlines about SNGX stock have been trending positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Soligenix earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
View the latest news about Soligenix
.

Are investors shorting Soligenix?

Soligenix saw a drop in short interest in January. As of January 15th, there was short interest totaling 127,300 shares, a drop of 19.4% from the December 31st total of 157,900 shares. Based on an average trading volume of 251,400 shares, the short-interest ratio is currently 0.5 days. Currently, 0.7% of the company's shares are short sold.
View Soligenix's Short Interest
.

Who are some of Soligenix's key competitors?

What other stocks do shareholders of Soligenix own?

Who are Soligenix's key executives?

Soligenix's management team includes the following people:
  • Dr. Christopher J. Schaber, Chairman, CEO & Pres (Age 53)
  • Ms. Karen R. Krumeich, CFO, Sr. VP & Corp. Sec. (Age 65)
  • Dr. Oreola Donini, Sr. VP & Chief Scientific Officer (Age 47)
  • Dr. Richard C. Straube, Sr. VP & Chief Medical Officer (Age 67)
  • Mr. Richard L. Dunning, Exec. Officer (Age 73)

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by many different retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.15%) and Wedbush Securities Inc. (0.06%). Company insiders that own Soligenix stock include Christopher J Schaber, Diane L Parks, Jerome B Zeldis and Mark E Pearson.
View institutional ownership trends for Soligenix
.

Which major investors are buying Soligenix stock?

SNGX stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and Wedbush Securities Inc.. Company insiders that have bought Soligenix stock in the last two years include Christopher J Schaber, Diane L Parks, Jerome B Zeldis, and Mark E Pearson.
View insider buying and selling activity for Soligenix
.

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $2.31.

How big of a company is Soligenix?

Soligenix has a market capitalization of $66.90 million and generates $4.60 million in revenue each year. The biopharmaceutical company earns $-9,360,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Soligenix employs 14 workers across the globe.

What is Soligenix's official website?

The official website for Soligenix is www.soligenix.com.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.